Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 4/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249432 | 0.84 | HRH4 (0.37) | HRH4HRH3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20249147 | 0.81 | LMNA (0.40) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18291587 | 0.81 | HRH4 (0.46) | HRH4PIM1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20249263 | 0.79 | CDK4 (0.39) | HRH4HRH3CDK4CDK6 | |
| SCHEMBL20249458 | 0.79 | MAP4K4 (0.44) | HRH3MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20249141 | 0.79 | LMNA (0.38) | HRH4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20249338 | 0.78 | HRH4 (0.34) | HRH4HRH3 | |
| SCHEMBL20038053 | 0.78 | HRH4 (0.41) | HRH4PIM1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13768899 | 0.78 | KMT2A (0.59) | MEN1KMT2ASMN1; SMN2PTPN11 | |
| SCHEMBL20249316 | 0.78 | HRH4 (0.40) | HRH4HRH3MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HRH4 1763/4885PIM1 596/4885HRH3 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.